Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug
discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain, and psychiatry. Prior to Origami, she was Vice President, Discovery Biology for Vertex Pharmaceuticals, where she generated and launched first-in-class blockbuster drugs in cystic fibrosis (Kalydeco, Orkambi, Symdeko, Trikafta).
